The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study

Overview

Journal J Clin Med Res

Specialty General Medicine

Date 2017 Apr 11

PMID 28392860

Citations 5

Authors

Hirokazu Kakuda

Junji Kobayashi

Masaru Sakurai

Masahiro Kakuda

Noboru Takekoshi

Affiliations

Soon will be listed here.

Abstract

Background: Postprandial hyperglycemia and hyperlipidemia are highly related to the development of atherosclerosis. Sodium/glucose cotransporter-2 (SGLT2) inhibitors have attracted attention as a new class of anti-diabetic agents for the treatment of type 2 diabetes. We investigated the effect of tofogliflozin on postprandial glucose and lipid metabolism in Japanese male patients with type 2 diabetes.

Methods: Ten Japanese men with type 2 diabetes (average age 66.3 years) were orally administered tofogliflozin (20 mg per day) for 8 weeks followed by a subsequent 8 weeks of washout of the agent. At 0, 8 and 16 weeks, postprandial metabolic parameters were measured at 0, 60 and 120 min after cookie ingestion.

Results: There were significant reductions in body weight and body mass index at 8 weeks. There was a reduction in HbA1c at 8 weeks, which returned to pretreatment levels at 16 weeks. Serum insulin levels did not change during the entire study period under either fasting or postprandial state. The area under the curve of plasma glucagon significantly increased at 8 weeks. There were no changes in lipid and lipoprotein levels either in fasting or postprandial state except for tendency toward reduction in postprandial triglycerides at 8 weeks and increase in HDL-C at 16 weeks.

Conclusions: Tofogliflozin treatment causes an improvement of postprandial glucose metabolism but not considerable postprandial lipid metabolism.

Citing Articles

Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.

Yanai H, Adachi H, Hakoshima M, Katsuyama H Int J Mol Sci. 2023; 24(18).

PMID: 37762244 PMC: 10530470. DOI: 10.3390/ijms241813942.

Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing....

Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M J Diabetes Investig. 2019; 10(6):1518-1526.

PMID: 31033218 PMC: 6825952. DOI: 10.1111/jdi.13066.

Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes.

Kakuda H, Kobayashi J, Sakurai M, Takekoshi N J Clin Med Res. 2019; 11(1):35-41.

PMID: 30627276 PMC: 6306130. DOI: 10.14740/jocmr3650.

Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy.

Hakoshima M, Yanai H, Kakuta K, Adachi H J Clin Med Res. 2018; 10(6):493-498.

PMID: 29707091 PMC: 5916538. DOI: 10.14740/jocmr3392w.

Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data.

Yanai H, Hakoshima M, Adachi H, Kawaguchi A, Waragai Y, Harigae T J Clin Med Res. 2017; 9(7):605-612.

PMID: 28611861 PMC: 5458658. DOI: 10.14740/jocmr3046w.

References

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K . Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group.... Cardiovasc Diabetol. 2014; 13:65. PMC: 4021346. DOI: 10.1186/1475-2840-13-65. View

Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E . Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013; 159(4):262-74. DOI: 10.7326/0003-4819-159-4-201308200-00007. View

Murai K, Katsuno T, Miyagawa J, Matsuo T, Ochi F, Tokuda M . Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data. Drugs R D. 2014; 14(4):301-8. PMC: 4311653. DOI: 10.1007/s40268-014-0072-6. View

Harano Y, Miyawaki T, Nabiki J, Shibachi M, Adachi T, Ikeda M . Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocr J. 2006; 53(2):173-80. DOI: 10.1507/endocrj.53.173. View

. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001; 161(3):397-405. DOI: 10.1001/archinte.161.3.397. View

Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H . Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008; 588(2-3):325-32. DOI: 10.1016/j.ejphar.2008.04.018. View

Kleta R, Stuart C, Gill F, Gahl W . Renal glucosuria due to SGLT2 mutations. Mol Genet Metab. 2004; 82(1):56-8. DOI: 10.1016/j.ymgme.2004.01.018. View

Nair S, Wilding J . Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2009; 95(1):34-42. DOI: 10.1210/jc.2009-0473. View

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A . Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999; 22(6):920-4. DOI: 10.2337/diacare.22.6.920. View

10.

Holm C, Kirchgessner T, Svenson K, Fredrikson G, Nilsson S, Miller C . Hormone-sensitive lipase: sequence, expression, and chromosomal localization to 19 cent-q13.3. Science. 1988; 241(4872):1503-6. DOI: 10.1126/science.3420405. View

11.

Slavin B, Ong J, Kern P . Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res. 1994; 35(9):1535-41. View

12.

Taira K, Hikita M, Kobayashi J, Bujo H, Takahashi K, MURANO S . Delayed post-prandial lipid metabolism in subjects with intra-abdominal visceral fat accumulation. Eur J Clin Invest. 1999; 29(4):301-8. DOI: 10.1046/j.1365-2362.1999.00454.x. View

13.

Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde A . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3):1020-31. DOI: 10.1210/jc.2011-2260. View

14.

ZILVERSMIT D . Atherogenesis: a postprandial phenomenon. Circulation. 1979; 60(3):473-85. DOI: 10.1161/01.cir.60.3.473. View

15.

Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K . Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter,.... Expert Opin Pharmacother. 2014; 15(6):749-66. DOI: 10.1517/14656566.2014.887680. View

16.

HAVEL R . Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol. 2000; 11(6):615-20. DOI: 10.1097/00041433-200012000-00008. View

17.

Bansal S, Buring J, Rifai N, Mora S, Sacks F, Ridker P . Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298(3):309-16. DOI: 10.1001/jama.298.3.309. View

18.

Misra M . SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2013; 65(3):317-27. DOI: 10.1111/j.2042-7158.2012.01574.x. View

19.

Barnett A . Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med. 2013; 125(5):92-100. DOI: 10.3810/pgm.2013.09.2698. View

20.

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View